Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
VOTER
1 other identifier
observational
150
1 country
10
Brief Summary
A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2019
Longer than P75 for all trials
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 25, 2019
CompletedFirst Posted
Study publicly available on registry
June 27, 2019
CompletedStudy Start
First participant enrolled
November 19, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
ExpectedFebruary 12, 2025
February 1, 2025
6.3 years
June 25, 2019
February 10, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of recurrent stroke or death
Recurrent stroke of any type or death from any cause
1 Year post-treatment
Secondary Outcomes (1)
Incidence of Restenosis
1 Year post-treatment
Interventions
This is a prospective registry looking at patients admitted for stroke with evidence of Vertebral Artery Origin Stenosis. Patients clinical outcomes will be collected at 30 days and 1-year post-treatment and angiographic outcomes at 1-year post-treatment
Eligibility Criteria
Patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
You may qualify if:
- Patients between 18 and 90 years of age
- Patient has experienced a posterior circulation ischemic event
- Patient has angiographically confirmed bilateral vertebral artery origin disease (Hypoplasia, occlusion, or stenosis).
- Patient has \>50% stenosis on the side being targeted for therapy
You may not qualify if:
- Pregnant women
- Contrast Indication to the use of anti-platelet drugs
- There is tandem vertebral or basilar artery stenosis
- The serum creatinin is \>2.5
- Baseline modified Rankin score is \>3
- \< 5 years life expectancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (10)
Baptist Medical Center Jacksonville
Jacksonville, Florida, 32207, United States
University of Southern Florida
Tampa, Florida, 33606, United States
Northwestern Medicine Regional Medical Group
Winfield, Illinois, 60190, United States
University of Iowa
Iowa City, Iowa, 52242, United States
SSM DePaul Hospital
Bridgeton, Missouri, 63044, United States
Saint Louis University
St Louis, Missouri, 63110, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Mercy Health Neuroscience Institute
Toledo, Ohio, 43608, United States
Semmes Murphey Clinic
Memphis, Tennessee, 38120, United States
Texas Tech University Health Science Center of El Paso
El Paso, Texas, 79905, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Randall Edgell, MD
St. Louis University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, Department of Neurology
Study Record Dates
First Submitted
June 25, 2019
First Posted
June 27, 2019
Study Start
November 19, 2019
Primary Completion
March 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
February 12, 2025
Record last verified: 2025-02